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http://dx.doi.org/10.1016/j.jacl.2014.12BACKGROUND: Because of variability in lipoprotein cholesterol content, low-density lipoprotein
(LDL) cholesterol frequently underrepresents or overrepresents the number of LDL particles. Mipo-
mersen is an antisense oligonucleotide that reduces hepatic production of apolipoprotein B–100, the
sole apolipoprotein of LDL.
OBJECTIVE: To characterize the effects of mipomersen on lipoprotein particle numbers as well as
subclass distribution using nuclear magnetic resonance (NMR) spectroscopy.
METHODS: We compared the tertiary results for the direct measurement of LDL particle numbers
by NMR among 4 placebo-controlled, phase 3 studies of mipomersen that had similar study designs but
different patient populations: homozygous familial hypercholesterolemia (HoFH), severe hypercholes-
terolemia, heterozygous familial hypercholesterolemia with established coronary artery disease, or
hypercholesterolemia with high risk for coronary heart disease (HC-CHD).
RESULTS: HoFH patients had the highest median total LDL particles at baseline compared with
HC-CHD patients, who had the lowest. At baseline, the HoFH population uniquely had a greater
mean percentage of large LDL particles (placebo, 60.2%; mipomersen, 54.9%) compared with small
LDL particles (placebo, 33.1%; mipomersen, 38.9%). In all 4 studies, mipomersen was associated
with greater reductions from baseline in the concentrations of small LDL particles compared with those
of large LDL particles, and both total LDL particles and small LDL particles were statistically signif-
icantly reduced.
CONCLUSIONS: Mipomersen consistently reduced all LDL particle numbers and preferentially
reduced the concentration of small LDL particles in all 4 phase 3 studies.
 2015 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).nica de Lıpides-InCor, HCFMUSP,
dar Bloco 2 Sala 4, 05403-900 S~ao
sp.br
pted for publication December 10,
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.008The treatment of hypercholesterolemia has been greatly
advanced by the use of 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA) reductase inhibitors, or statins, which
became widely available in the 1990s.1 However, in indi-
viduals with severe hypercholesterolemia (Severe-HC),nder the CC BY-NC-ND license (http://creativecommons.org/licenses/
Figure 1 Study design for the 4 phase 3, randomized, double-
blind, placebo-controlled trials of mipomersen in patients
receiving maximally tolerated lipid-lowering therapy. * indicates
#4-week screening period; † indicates 2:1 mipomersen 200 mg/
wk versus placebo.
202 Journal of Clinical Lipidology, Vol 9, No 2, April 2015particularly those with familial hypercholesterolemia (FH),
even high-dose statin therapy and adjuvant treatments (such
as ezetimibe, resins, and niacin) may not be sufficient to
achieve target low-density lipoprotein (LDL) levels in a
significant number of patients.2,3
Statins act by reducing the production of cholesterol
through inhibition of the rate-limiting enzyme HMG-CoA
reductase in cholesterol synthesis.4 The result is an upregu-
lation of LDL receptors (LDLRs) in peripheral tissues and a
subsequent increase in LDL particle clearance from the cir-
culation.5 However, individuals with FH have both
increased production of LDL particles6,7 and, because
they have dysfunctional LDLR, markedly decreased
LDLR-mediated clearance of LDL particles.5,6 In patients
with homozygous FH (HoFH) who have a near-complete
or a complete loss of LDLR functionality, this pattern is
even more pronounced.5
Statin therapy does offer benefit to patients with HoFH.
A recent retrospective study of 149 patients demonstrated
that statins were associated with delayed cardiovascular
events and prolonged survival in patients with HoFH,
whereas patients who go untreated rarely survive beyond
the second decade of life.1 However, a substantial number
of patients with HoFH have persistently high plasma levels
of LDL despite receiving maximally tolerated lipid-
lowering therapy.3,8
Mipomersen, a therapeutic option with a unique mode of
action that differs from that of statins, is approved for the
treatment of HoFH in the United States.9 Mipomersen is a
20-nucleotide, second-generation, antisense oligonucleo-
tide that inhibits human apolipoprotein B (apo B)–100 pro-
duction by sequence-specific binding to its messenger RNA
(mRNA), causing degradation of the mRNA through
enzyme-mediated pathways or disruption of mRNATable 1 Patient population and key inclusion criteria
Patient population Inclusion criteria*
HoFH  Age $12 y
 Genetic confirmation of HoFH
 Xanthoma before age 10 y or
 LDL-C level $130 mg/dL and
Severe-HC  Age $18 y
 Diagnosis of severe hyperchol
 Triglyceride level ,350 mg/d
HeFH-CAD  Age $18 y
 Diagnosis of HeFH
 LDL-C level $100 mg/dL with
 Presence of CAD
HC-CHD  Age $18 y
 Documented history of CHD o
 LDL-C level $100 mg/dL with
CAD, coronary artery disease; CHD, coronary heart disease; HC-CHD, hyperc
HeFH, heterozygous familial hypercholesterolemia; HeFH-CAD, heterozygous fam
study subjects; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-
study subjects.
*Patients in all studies were required to be taking maximally tolerated dosfunction through binding alone.9,10 Because apo B–100 is
an essential structural component of very low–density lipo-
protein (VLDL), intermediate-density lipoprotein (IDL),
LDL, and lipoprotein(a) [Lp(a)], its decreased production
by mipomersen leads to reduced circulating levels of these
atherogenic lipoprotein particles.11–14
Traditionally, the concentration of circulating LDL has
been estimated by measuring cholesterol contained in LDL
particles (LDL-C). Alternatively, the number of LDL
particles (LDL-P) can be quantified directly by nuclear
magnetic resonance (NMR) spectroscopy, as well as
estimated by measurement of apo B. Because of a variety
of metabolic abnormalities (eg, insulin resistance, meta-
bolic syndrome, type 2 diabetes mellitus), as well as use of
pharmacologic therapy, the cholesterol content of lipopro-
tein particles varies widely among individuals.15–19 Conse-
quently, frequent discordance is noted between cholesterol
(LDL-C) and particle number (NMR LDL-P, apo B) mea-
sures of LDL quantity in which LDL-C frequently under-
represents or overrepresents the LDL-P.15,16,20–22
When cholesterol (LDL-C) and particle number mea-
sures (apo B or NMR LDL-P) of LDL quantity are
discordant, cardiovascular risk tracks with particle number,or history of untreated LDL-C level .500 mg/dL
evidence of HeFH in both parents
triglyceride level ,350 mg/dL
esterolemia: LDL-C level $300 mg/dL or $200 mg/dL with CHD
L
triglyceride level ,200 mg/dL
r CHD risk equivalents
triglyceride level ,200 mg/dL
holesterolemia and high risk for coronary heart disease study subjects;
ilial hypercholesterolemia and documented stable coronary artery disease
density lipoprotein cholesterol; Severe-HC, severe hypercholesterolemia
es of lipid-lowering medications.
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Santos et al Reduction of small LDL-P by mipomersen 203not cholesterol.19,22–24 As a result, several expert panels
recommend the use of apo B or NMR LDL-P as a target
of therapy to guide management and adjudicate response
to pharmacotherapy in patients with increased cardiovascu-
lar risk.23,25–29 The evaluation of LDL-P by either apo B or
LDL-P determinations was shown to be a better discrimi-
nator of cardiovascular disease risk than LDL-C.23
Recently, the American Association for Clinical Chemistry
published a comprehensive review comparing apo B and
NMR LDL-P with diverse cardiovascular outcomes.30
Among 25 studies reviewed, both apo B and LDL-P were
significantly associated with at least 1 outcome in 21 of
the 25 studies (84.0%). Furthermore, apo B and LDL-P
were compared in a total of 85 outcomes reported in these
studies. In 50 of 85 comparisons (58.8%), both apo B and
LDL-P were significantly associated with clinical out-
comes. However, a substantial amount of discordance
(21.2%) was noted in which one biomarker was statistically
significant whereas the other was not. In these cases, LDL-
P showed a significant association with a clinical outcome
more often than apo B. Although limited data were avail-
able for review, the authors reasoned these findings could
relate to differences in the analytical methods used to mea-
sure these biomarkers.
Four phase 3, randomized, double-blind, placebo-
controlled trials have demonstrated that mipomersen
significantly reduces LDL-C, apo B, total cholesterol,
non–high-density lipoprotein cholesterol (non–HDL-C),
and Lp(a) in patients who are already receiving maximally
tolerated lipid-lowering therapy and who have HoFH,
Severe-HC, heterozygous FH (HeFH) with established
coronary artery disease (CAD), or hypercholesterolemia
with high risk for CHD.11–14 This article reports on the pre-
specified tertiary end point results of these 4 phase 3
studies, namely, the effects of mipomersen on lipoprotein
particle numbers as well as subclass distribution using
NMR.Ta
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.Materials and methods
NMR lipoprotein analysis was a prespecified tertiary end
point analysis in 4 phase 3, randomized, double-blind,
placebo-controlled, multicenter trials with similar study
designs (Fig. 1), for which primary analyses have been pre-
viously published.11–13 The primary objectives of all 4
studies were to compare the additive effects of mipomersen
vs placebo in patients receiving a maximally tolerated lipid-
lowering regimen. Each of the 4 trials included patients
with varying degrees of hypercholesterolemia (ranging
from HoFH to Severe-HC): (1) HoFH; (2) Severe-HC; (3)
HeFH and documented stable CAD (HeFH-CAD); and
(4) hypercholesterolemia and high risk for coronary heart
disease events (HC-CHD) (Table 1).14 In the HC-CHD
study, patients were included who had CHD or a CHD
risk equivalent, including diabetes mellitus, or multiple
risk factors that placed them at .20% risk for CHD over
Table 3 Mean percentage of low-density lipoprotein (LDL) subclasses at baseline
Study
Placebo (N 5 129) Mipomersen (N 5 261)
Small LDL (%) Large LDL (%) IDL (%) Small LDL (%) Large LDL (%) IDL (%)
HoFH (N 5 51) 33.1 60.2 6.7 38.9 54.9 6.3
Severe-HC (N 5 58) 55.2 40.2 4.5 54.7 39.8 5.6
HeFH-CAD (N 5 124) 61.8 35.2 3.1 62.0 34.2 3.8
HC-CHD (N 5 157) 67.5 28.8 3.8 68.1 28.6 3.3
HC-CHD, hypercholesterolemia and high risk for coronary heart disease study; HeFH-CAD, heterozygous familial hypercholesterolemia and documented
stable coronary artery disease study; HoFH, homozygous familial hypercholesterolemia study; IDL, intermediate-density lipoproteins; Severe-HC, severe
hypercholesterolemia study.
204 Journal of Clinical Lipidology, Vol 9, No 2, April 201510 years as defined by the National Cholesterol Education
Program, Adult Treatment Panel III Guidelines.31
All patients were receiving maximally tolerated lipid-
lowering therapy at the study entry, including statins in
98.0% of patients (50 of 51) in the HoFH study, and in all
patients in the Severe-HC (N 5 58), HeFH-CAD
(N 5 124), and HC-CHD (N 5 157) studies.11–14 No 2 pa-
tients were on LDL apheresis within 8 weeks of the
screening visit.11–13
Patients were randomized 2:1 to receive either weekly
subcutaneous injections of 200 mg mipomersen or placebo
for 26 weeks. All 4 protocols included measurements of
lipid subclass concentrations at a minimum at weeks 1 and
28 (or at the early termination visit for those who
discontinued early). All blood samples were collected
before study drug administration after a fast of more than
10 hours. The primary efficacy end point was percentage
reduction from baseline in LDL-C level. Secondary end
points were percentage reductions from baseline in apo B
total cholesterol and non–HDL-C levels. Tertiary end
points included percentage changes in triglycerides,
Lp(a), VLDL cholesterol, LDL-C-to-HDL ratio, apolipo-
protein A-1 (apo A-1), HDL-C, and lipoprotein subclasses.
Plasma lipid and apolipoprotein determinations
Determinations of plasma lipids and apolipoproteins
were done at a central laboratory (Medpace Reference
Laboratories, Cincinnati, OH, USA; and Leuven, Belgium).Table 4 Percentage change from baseline in LDL-C, apo B, and Lp(a)
Patient population (N 5 256)
LDL-C ap
Baseline (mg/dL) Change (%) Ba
HoFH (N 5 34) 439 ‒25 28
Severe-HC (N 5 39) 276 ‒36 20
HeFH-CAD (N 5 82) 153 ‒28 13
HC-CHD (N 5 101) 123 ‒37 11
apo B, apolipoprotein B; CAD, coronary artery disease; CHD, coronary
hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C
*P values for all LDL-C and Lp(a) percentage changes from baseline within
shown as mean. Patients received mipomersen 200 mg weekly administered suConcentrations of total cholesterol, HDL-C, and triglycer-
ides were measured by enzymatic colorimetry. HDL was
isolated after dextran sulfate precipitation of VLDL and
LDL. LDL-C concentration was calculated by the Friede-
wald formula (or after ultracentrifugation if triglyceride
concentration was.4.5 mmol/L). Lp(a) was measured by a
rate nephelometric assay standardized to Northwest Lipid
Research Clinic (Seattle, WA, USA). Apo B and apo A-1
were measured by nephelometry.
Lipoprotein particle methodology
Lipoprotein subclass concentrations were performed by
Liposcience, Inc (Raleigh, NC, USA) using NMR spec-
troscopy.32 Concentrations are presented as quantity per
volume (nanomoles per liter) rather than by weight (grams)
to best reflect particle numbers.32 LDL particle subclasses
were defined by Liposcience, Inc as follows: IDL (23–
27 nm), large LDL (21.2–23 nm), and small LDL (18–
21.2 nm). Diameters are consistent with data from electron
microscopy, being approximately 5 nm smaller than diam-
eters obtained with gradient gel electrophoresis. Total LDL-
P was composed of the sum of IDL, small LDL, and large
LDL fractions.32
Statistical methods
The analyses reported included all randomized patients
who received at least 1 injection of the study drug unlesslevels in patients given mipomersen across the 4 phase 3 trials*
o B Lp(a)
seline (mg/dL) Change (%) Baseline (nmol/L) Change (%)
3 ‒27 2284.8 ‒31
2 ‒36 2177.7 ‒33
3 ‒26 2284.8 ‒20
7 ‒38 1927.8 ‒24
heart disease; HC, hypercholesterolemia; HeFH, heterozygous familial
, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a).
the mipomersen group are ,.001. LDL-C and apo B results and Lp(a) are
bcutaneously for 26 weeks.
Figure 2 Median percentage change from baseline in total and subclasses of low-density lipoprotein particle (LDL-P) and intermediate-
density lipoprotein particle (IDL-P) numbers for the mipomersen and placebo groups of all 4 phase 3 trials. HC-CHD, hypercholesterolemia
and high risk for coronary heart disease study subjects; HeFH-CAD, heterozygous hypercholesterolemia and documented stable coronary
artery disease study subjects; HoFH, homozygous familial hypercholesterolemia study subjects; Severe-HC, severe hypercholesterolemia
study subjects.
Santos et al Reduction of small LDL-P by mipomersen 205otherwise specified. The baseline value for levels of lipids
and/or lipoproteins was defined as the average of the
sample taken at screening (,4 weeks before study day 1)
and the sample taken on day 1 (pretreatment). If the
difference between the 2 measurements was greater than
12%, then the day 1 value was used. The end point was
week 28. Data were presented as nominal change from
baseline. Determination of P values was performed only for
comparisons of the efficacy parameters between treatment
groups, with a conclusion of statistical significance if
P, .05. P values for the between-group comparisons of ab-
solute change from baseline to end point for total LDL-P,
subclasses, and mean LDL-P size were based on the Wil-
coxon rank sum test.Results
Patient demographics and baseline characteristics are
presented in Table 2. The mean age of patients in the HoFH
study at baseline was 31.3 years (median, 31 years; range,
22–53 years), which was noticeably lower than that of the
other 3 studies. The studies recruiting subjects at risk for
or having CAD (ie, the HeFH-CAD study and the HC-
CHD study) had a greater percentage of males than the
HoFH study and the Severe-HC study. Metabolic syndrome
was the most prevalent in the HC-CHD study (72% of pa-
tients) compared with the other studies: HoFH (15.7%),
HeFH-CAD (37.1%), and Severe-HC (39.7%). Baseline
triglyceride levels were higher in the HC-CHD andSevere-HC studies than in the HoFH and HeFH studies,
and baseline LDL was the highest in the HoFH study.
Data for LDL subclasses were available for most
patients. In the HoFH study, data were missing at end
point for 1 of 17 patients and 3 of 34 patients in the placebo
and mipomersen groups, respectively. In the Severe-HC
study, end point data were missing for 1 of 19 patients and
3 of 39 patients in the placebo and mipomersen groups,
respectively. In the HeFH-CAD study, baseline data were
missing for 1 of 41 patients in the placebo group, and
baseline and end point data were missing for 2 of 83
patients in the mipomersen group. In the HC-CHD study,
data were not available at end point for 3 of 52 patients and
10 of 105 patients in the placebo and mipomersen groups,
respectively. Across the 4 studies, injection-site reactions
and flu-like symptoms were among the most common
adverse events leading to study discontinuation for patients
treated with mipomersen.
Baseline lipoprotein analysis
Patients with HoFH had the highest median total LDL-P
at baseline compared with patients with HC-CHD, who had
the lowest. When the concentrations of LDL subclasses
were compared relative to each other (Table 3), the popula-
tion with HoFH given placebo or mipomersen, respectively,
had a greater mean percentage of large LDL particles
(60.2% or 54.9%) than small LDL particles (33.1% or
38.9%). This result contrasted with results of the 3 other
study populations (Severe-HC, HeFH-CAD, and HC-
Table 5 Median particle concentrations and change from baseline in LDL-P in patients given mipomersen or placebo in the 4 phase 3 trials
Patient population
Placebo Mipomersen
P value*
Baseline, nmol/L
(P25, P75)
End point nmol/L
(P25, P75)
Nominal change
nmol/L (P25, P75)
Baseline nmol/L
(P25, P75)
End point nmol/L
(P25, P75)
Nominal change
nmol/L (P25, P75)
HoFH
Total LDL-P 2212 (1802, 3502) 2771 (1765, 3637) 237 (–235, 539) 2917 (2127, 3624) 1925 (1538, 2685) –882 (–1263, –351) ,.001
IDL 148 (67, 258) 117 (29, 266) –12 (–115, 26) 198 (88, 257) 84 (0, 230) –45 (–180, 0) .317
Large LDL 1542 (1228, 2036) 1786 (1098, 2208) –138 (–233, 253) 1619 (1318, 2047) 1378 (1101, 1894) –119 (–477, 94) .356
Small LDL 505 (384, 1208) 505 (289, 1823) 143 (–122, 481) 849 (195, 1848) 199 (47, 723) –559 (–1090, –90) ,.001
Mean LDL particle size, nm (SD) 21.9 (0.7) 21.8 (0.8) –0.1 (0.5) 21.7 (0.9) 22.1 (0.8) 0.5 (0.6) .002
Severe-HC
Total LDL-P 2210 (1619, 2881) 2381 (1725, 2634) 162 (–17, 573) 2470 (1860, 2978) 1216 (1012, 2003) –931 (–1670, –389) ,.001
IDL 115 (53, 156) 101 (57, 186) 15 (–56, 64) 157 (44, 215) 36 (16, 94) –100 (–129, –1) .004
Large LDL 967 (466, 1165) 1009 (595, 1169) 65 (–214, 162) 972 (771, 1263) 634 (525, 1008) –274 (–517, 37) .018
Small LDL 1115 (662, 1618) 1355 (817, 1570) 43 (–125, 596) 1173 (588, 1984) 507 (181, 696) –484 (–1210, –164) ,.001
Mean LDL particle size, nm (SD) 21.1 (0.7) 21.1 (0.6) –0.1 (0.5) 21.2 (0.9) 21.7 (0.7) 0.51 (0.7) .002
HeFH-CAD
Total LDL-P 1490 (1316, 1829) 1664 (1390, 2044) 82 (–66, 381) 1651 (1337, 2000) 1173 (881, 1416) –457 (–787, –82) ,.001
IDL 21 (5, 75) 26 (5, 90) 4 (–21, 31) 48 (8, 91) 25 (4, 55) –19 (–54, 6) .010
Large LDL 526 (379, 662) 513 (371, 691) 42 (–73, 104) 561 (380, 733) 488 (360, 574) –121 (–285, 56) .001
Small LDL 916 (762, 1186) 988 (726, 1372) 87 (–118, 365) 989 (670, 1469) 664 (284, 953) –268 (–593, –65) ,.001
Mean LDL particle size, nm (SD) 21 (0.6) 21 (0.7) –0.1 (0.5) 21 (0.8) 21 (0.9) 0.3 (0.6) .001
HC-CHD
Total LDL-P 1400 (1150, 1593) 1356 (1118, 1671) –20 (–219, 106) 1462 (1231, 1718) 796 (558, 1141) –590 (–956, –292) ,.001
IDL 33 (14, 89) 37 (8, 70) –9 (–33, 16) 37 (9, 87) 16 (3, 45) –12 (–48, 11) .363
Large LDL 390 (269, 576) 363 (253, 445) –15 (–102, 80) 446 (248, 550) 317 (225, 425) –64 (–220, 52) ,.001
Small LDL 978 (649, 1209) 883 (678, 1257) –17 (–275, 98) 994 (741, 1246) 451 (234, 723) –478 (–784, –287) ,.001
Mean LDL particle size, nm (SD) 20.7 (0.8) 20.7 (0.8) 0.01 (0.54) 20.7 (0.7) 21.3 (0.8) 0.58 (0.76) ,.001
HC-CHD, hypercholesterolemia and high risk for coronary heart disease study subjects; HeFH-CAD, heterozygous familial hypercholesterolemia and documented stable coronary artery disease study subjects;
HoFH, homozygous familial hypercholesterolemia study subjects; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDL-P, low-density lipoprotein particle number; P, percentile; SD,
standard deviation; Severe-HC, severe hypercholesterolemia study subjects.
*P value is for the between-group comparison of absolute change from baseline to end point via Wilcoxon rank sum test.
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Santos et al Reduction of small LDL-P by mipomersen 207CHD), all of which had a larger mean percentage of small
LDL particles than large LDL particles.
Within each study, baseline values for total LDL-P and
subclasses were not statistically different between treat-
ment groups.
LDL subclass analysis
Previously published efficacy results from the 4 phase 3
studies demonstrated that mipomersen effectively lowered
all the atherogenic lipid levels: LDL-C, apo B, and Lp(a)
(Table 4).11–14 This analysis shows that mipomersen treat-
ment was associated with a reduction from baseline in the
number of all LDL subclasses (Fig. 2). In all 4 studies,
greater reductions from baseline were seen in the concen-
trations of small LDL particles than those of large LDL par-
ticles. In the mipomersen groups, median percentage
changes from baseline in concentrations of small LDL vs
large LDL, respectively, were as follows: HoFH, –59.8%
vs –7.1%; Severe-HC, –59.8% vs –28.1%; HeFH-CAD,
–36.5% vs –18.7%; and HC-CHD, –51.1% vs –15.1%
(Fig. 2).
When the 2 treatment groups were compared, mipo-
mersen treatment was associated with a statistically signif-
icant reduction in total LDL-P and number of small LDL in
all 4 studies (Table 5). The median large LDL and IDL con-
centrations were significantly reduced with mipomersen
treatment in the Severe-HC and HeFH-CAD study subjects;
however, reductions for large LDL and IDL in HoFH and
IDL in HC-CHD study subjects did not reach statistical sig-
nificance. Because of mean changes in the concentrations
of LDL subclasses, mean LDL particle size increased
significantly in all 4 studies by an average of 0.5 nm
(P # .002).Discussion
Results from 4 previously published phase 3 studies
demonstrated that mipomersen effectively lowered apo
B–containing lipoproteins.11–14 In this tertiary end point
analysis, we show that mipomersen reduces the LDL-P
within all subclasses; however, mipomersen preferentially
reduces the concentrations of small LDL particles and
has less effect on the concentrations of large LDL
particles.
The NMR lipoprotein analysis showed that the trial
populations had distinct LDL particle profiles at baseline.
Patients in the HoFH study had a greater percentage of
large vs small LDL particles. Patients in the Severe-HC
study had elevated levels of both large and small LDL
particles, whereas patients in the HeFH-CAD and HC-CHD
studies had greater amounts of small LDL particles. These
observations are not unexpected because individuals with
HoFH generally are not insulin resistant33; only 15.7% in
the HoFH study were found to have metabolic syndrome,
a condition usually associated with increased small LDL-Ps. In contrast, 37% to 72% of individuals in the other 3
studies had metabolic syndrome. A number of studies
support an inverse association between insulin sensitivity
and increased preponderance of smaller LDL parti-
cles.16,17,34–38 Previously published works report similar
observations of larger, more buoyant LDL particles being
associated with FH.39–41
Moreover, in HoFH, there is a total or a near-total lack
of LDLR function.42 One plausible explanation for the as-
sociation of mipomersen with a preferential reduction in
small LDL particles may relate to decreased VLDL produc-
tion, which drives the production of small LDL. Mipo-
mersen acts by reducing the production of apo B and
subsequently the production of apo B–containing lipopro-
teins. Large triglyceride-rich VLDL may undergo slow
metabolism and have a greater chance of remodeling via
cholesterol ester transfer protein to lose cholesterol ester
and gain triacylglycerol, thus priming it for conversion to
small, dense LDL by hepatic lipase.43 A reduction in
triacylglycerol-rich VLDL would therefore reduce the
amount of small LDL.
Another possible mechanism for the preferential reduc-
tion of small LDL subclasses by mipomersen may be
related to its selective effect on apolipoprotein C-III (apo
C-III) compared with apolipoprotein E (apo E) and the
activity of hepatic lipase.44 Apo E–containing triglyceride-
rich lipoproteins generally undergo clearance by the liver
and have a low tendency to continue the lipolytic process
to form LDL.45 Apo C-III antagonizes the action of apo E
and channels particles to lipolysis and LDL formation.45
By reducing apo C-III, mipomersen may be associated
with increased clearance of VLDL and IDL particles,
which would result in fewer particles processing through
lipolytic cascade and reduce the small LDL-P.18,23,43,45
A recent systematic literature review of 36 published
studies supports our observations of differential reduction
in small LDL-P. The review focused on variations in effect
on LDL markers (including LDL-P and LDL-C) by several
common pharmacotherapies (statins, fibrates, niacin, resins,
and anti–apo B oligonucleotides [ie, mipomersen]).46 The
amount of cholesterol per LDL particle varies among pa-
tients, such as those with metabolic syndrome, resulting
in variation in reductions of LDL-C and LDL-P levels by
different classes of pharmacotherapy.46
In conclusion, mipomersen, which has demonstrated an
acceptable safety and tolerability profile in the target
patient population in previous studies,11–14 consistently
reduced all LDL-Ps and preferentially reduced the concen-
tration of small LDL particles in all 4 phase 3 studies. Pro-
spective clinical trials are warranted to further explore the
clinical significance of these findings.Acknowledgments
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